CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Active· 11 enrolled
Drug / intervention
Durvalumab (Medi4736) +1 moredrug
Likely dose
Durvalumab (Medi4736) 1500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03215095
NCT03215095Early Ph 1Active
CompareCT.gov

Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers

Memorial Sloan Kettering Cancer Center·interventional·Posted Jul 12, 2017·Updated Jul 17, 2025

In Brief

A Early Phase 1 clinical trial evaluating Durvalumab (Medi4736) and Radioiodine (RAI) for Thyroid Cancer. Active but no longer recruiting, targeting 11 participants across 7 sites.

Detailed Summary

The purpose of this study is to find out what effects, good and/or bad, a drug called durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer. Durvalumab is a drug that has been developed to activate the immune system by blocking a protein called programmed death ligand-1 (PD-L1) that can be present on tumor and normal cells, including immune cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesUnited States
CollaboratorsAstraZeneca, MedImmune LLC

Timeline

Early Ph 1ActiveOverdue
201820192020202120222023202420252026
First PostedJul 12, 2017
Enrollment StartJul 10, 2017
Primary CompletionFeb 6, 2023
Study CompletionJul 1, 2026
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 9.0 years ago

Interventions

Durvalumab (Medi4736)drug

durvalumab 1500 mg IV every 4 weeks

Radioiodine (RAI)radiation

100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.